Alexandria Forbes
Chief Executive Officer at MEIRAGTX HOLDINGS PLC
Net worth: 9 M $ as of 2024-03-30
Profile
Alexandria Forbes was the founder of Meadowvale Partners Capital Management LLC.
She currently holds three positions as President, Chief Executive Officer & Director at MeiraGTx Holdings Plc, Director at Kadmon Corp.
LLC, and Director at MeiraGTx Ltd.
Her former positions include Managing Director-Biotechnology Research at Galleon Management LP, Managing Director at Sivik Global Healthcare LLC (Old), and Director at Kadmon Holdings, Inc. from 2015 to 2018.
Forbes holds a doctorate degree from the University of Oxford and a graduate degree from the University of Cambridge.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
MEIRAGTX HOLDINGS PLC
2.20% | 2024-04-04 | 1,401,489 ( 2.20% ) | 9 M $ | 2024-03-30 |
Alexandria Forbes active positions
Companies | Position | Start |
---|---|---|
MEIRAGTX HOLDINGS PLC | Chief Executive Officer | 2015-03-19 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Director/Board Member | 2009-12-31 |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Director/Board Member | 2015-03-19 |
Former positions of Alexandria Forbes
Companies | Position | End |
---|---|---|
KADMON HOLDINGS, INC. | Chief Operating Officer | 2015-03-31 |
Sivik Global Healthcare LLC (Old)
Sivik Global Healthcare LLC (Old) Investment ManagersFinance Sivik Global Healthcare LLC, formerly Argus Management LLC, is a New York City-based hedge fund manager founded by former members of Galleon Management. | Analyst-Equity | 2008-12-30 |
Galleon Management LP.
Galleon Management LP. Investment ManagersFinance Founded in 1997, Galleon Management LP (The Galleon Group) is a New York City-based hedge fund manager. | Corporate Officer/Principal | - |
Meadowvale Partners Capital Management LLC
Meadowvale Partners Capital Management LLC Investment ManagersFinance Meadowvale Partners Capital Management LLC is a hedge fund manager located in New York City. The firm manages the Meadowvale Family of Funds. | Founder | - |
Training of Alexandria Forbes
University of Oxford | Doctorate Degree |
University of Cambridge | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MEIRAGTX HOLDINGS PLC | Health Technology |
Private companies | 6 |
---|---|
Galleon Management LP.
Galleon Management LP. Investment ManagersFinance Founded in 1997, Galleon Management LP (The Galleon Group) is a New York City-based hedge fund manager. | Finance |
Sivik Global Healthcare LLC (Old)
Sivik Global Healthcare LLC (Old) Investment ManagersFinance Sivik Global Healthcare LLC, formerly Argus Management LLC, is a New York City-based hedge fund manager founded by former members of Galleon Management. | Finance |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Meadowvale Partners Capital Management LLC
Meadowvale Partners Capital Management LLC Investment ManagersFinance Meadowvale Partners Capital Management LLC is a hedge fund manager located in New York City. The firm manages the Meadowvale Family of Funds. | Finance |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Alexandria Forbes